SCHEMBL5136157

SCHEMBL5136157

O=C(c1ccccc1-n1cccc1)N(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.59
KDM4E B2RXH2 1/20 0.58
ALDH1A1 P00352 2/20 0.51
MAPK1 P28482 1/20 0.50
TDP1 Q9NUW8 2/20 0.48
CFTR P13569 2/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5053435 0.92 TSHR (0.51) TSHRKDM4EALDH1A1MAPK1TDP1
SCHEMBL5136268 0.88 TSHR (0.53) TSHRKDM4EALDH1A1MAPK1TDP1
SCHEMBL5136588 0.87 TSHR (0.47) TSHRKDM4EALDH1A1MAPK1TDP1
SCHEMBL5134505 0.86 PKM (0.51) TSHRKDM4EMAPK1CYP2C9HDAC3
SCHEMBL5135328 0.81 TDP1 (0.58) TSHRKDM4EALDH1A1TDP1MAPT
SCHEMBL5135828 0.80 TDP1 (0.57) TSHRKDM4EALDH1A1TDP1CYP2C9
SCHEMBL12172745 0.80 TSHR (0.71) TSHRKDM4EALDH1A1MAPK1TDP1
SCHEMBL29370283 0.80 TSHR (0.71) TSHRKDM4EALDH1A1MAPK1TDP1
SCHEMBL5136943 0.79 TSHR (0.51) TSHRTDP1MEN1KMT2A
SCHEMBL23707941 0.79 TSHR (0.56) TSHRKDM4EMAPK1TDP1CFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed